Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	38.94	29.8	11.32	7.11	7.83	8.54
Cash & Short-Term Investments	38.94	29.8	11.32	7.11	7.83	8.54
Cash Growth	79.14%	163.34%	59.23%	-9.27%	-8.24%	167.33%
Receivables	50.44	59.72	29.21	19.45	3.09	3.06
Inventory	24.2	21.26	16.24	12.93	9.55	6.74
Prepaid Expenses	0.91	1.33	0.98	0.52	1.03	0.53
Total Current Assets	114.49	112.11	57.74	40.01	21.51	18.86
Property, Plant & Equipment	13.32	13.01	14.1	14.61	10.44	6.98
Other Intangible Assets	-	-	0.29	0.29	0.29	0.47
Long-Term Deferred Tax Assets	6.5	7.82	18.37	22.16	2.17	2.17
Long-Term Deferred Charges	4.79	4.79	5.35	6.05	6.05	6.17
Other Long-Term Assets	0.57	0.56	0.55	0.53	0.43	0.5
Total Assets	139.67	138.29	96.39	83.65	40.9	35.15

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	5.59	6.05	2.96	2.71	2.45	1.43
Accrued Expenses	5.37	9.6	3.45	4.82	4.63	4.28
Short-Term Debt	-	-	4	4	-	-
Current Portion of Long-Term Debt	0.23	0.23	0.25	0.3	0.31	0.35
Current Portion of Leases	0.94	0.92	0.84	0.72	0.01	0.2
Current Income Taxes Payable	1.06	0.59	0.34	0.49	0.41	0.41
Current Unearned Revenue	-	-	0.01	0.01	0.01	0.01
Other Current Liabilities	17.25	-	-	-	-	-
Total Current Liabilities	30.44	17.39	11.84	13.05	7.83	6.69
Long-Term Debt	2.78	2.8	3.03	3.28	3.56	1.39
Long-Term Leases	1.62	1.87	2.8	3.44	-	0.84
Long-Term Unearned Revenue	-	-	-	0.01	0.02	0.03
Other Long-Term Liabilities	-	17.34	25.2	6.3	0.52	0.98
Total Liabilities	34.84	39.41	42.87	26.07	11.94	9.93

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	1.08	1.08	1.07	1.07	1.01	1.01
Additional Paid-In Capital	173.98	173.94	173.46	173.21	164.75	164.58
Retained Earnings	-69.92	-75.83	-120.7	-116.39	-136.5	-140.06
Treasury Stock	-0.31	-0.31	-0.31	-0.31	-0.31	-0.31
Total Common Equity	104.83	98.88	53.52	57.58	28.96	25.22
Shareholders' Equity	104.83	98.88	53.52	57.58	28.96	25.22
Total Liabilities & Equity	139.67	138.29	96.39	83.65	40.9	35.15

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	5.57	5.82	10.91	11.74	3.89	2.78
Net Cash (Debt)	33.37	23.98	0.4	-4.63	3.94	5.75
Net Cash Growth	121.52%	5888.11%	-	-	-31.44%	606.63%
Net Cash Per Share	0.03	0.02	0.00	-0.00	0.00	0.01
Filing Date Shares Outstanding	1,077	1,077	1,068	1,068	1,014	1,011
Total Common Shares Outstanding	1,077	1,077	1,068	1,068	1,014	1,011
Working Capital	84.05	94.72	45.9	26.96	13.68	12.17
Book Value Per Share	0.10	0.09	0.05	0.05	0.03	0.02
Tangible Book Value	104.83	98.88	53.23	57.29	28.67	24.76
Tangible Book Value Per Share	0.10	0.09	0.05	0.05	0.03	0.02
Land	11.91	11.65	11.65	11.06	10.77	5.46
Machinery	17.18	16.63	15.71	15.02	14.24	13.85

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error